BioCentury | Dec 2, 2019
Company News

Innovent’s Tyvyt edges out PD-1s on China’s 2020 reimbursement list

...NYSE:JNJ) gained through its 2017 acquisition of Actelion Ltd.: Opsumit macitentan, Uptravi selexipag and Tracleer bosentan. Stephen...
BioCentury | Nov 15, 2019
Product Development

Chipping away at unreliable animal data

...Janssen Pharmaceutical Research and Development on the study, which evaluated eight products including approved drugs bosentan...
...chip platform to enable better decision making in drug discovery and development." Geraldine Hamilton, Emulate Bosentan...
BioCentury | Feb 22, 2019
Politics & Policy

China releases list of rare disease drugs with reduced VAT

...metabolic disorders such as phenylketonuria, Pompe disease and Gaucher disease. Drugs for PAH include Tracleer bosentan...
...and Ofev/Vargatef nintedanib from Boehringer Ingelheim GmbH (Ingelheim, Germany). Also included are the APIs for bosentan...
BioCentury | Mar 1, 2018
Politics & Policy

Biopharma wants another bite at the donut hole

...in place: the Actelion Pharmaceuticals Ltd. unit of Johnson & Johnson (NYSE:JNJ), which markets Tracleer bosentan...
BioCentury | Oct 6, 2017
Finance

Bargain shopping

...with myelodysplasia-related changes Johnson & Johnson (NYSE:JNJ) FDA approves a 32 mg tablet of Tracleer bosentan...
BioCentury | Sep 8, 2017
Clinical News

FDA approves Tracleer for pediatric PAH

...FDA approved a 32 mg tablet of Tracleer bosentan to treat pulmonary arterial hypertension in children...
...Johnson & Johnson (NYSE:JNJ) gained Tracleer in its June acquisition of Actelion Ltd. Actelion said Tracleer...
...Jan. 27 ). Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Product: Tracleer bosentan Business: Cardiovascular Mary Romeo Tracleer Idorsia...
BioCentury | Sep 6, 2017
Company News

FDA approves Tracleer for pediatric PAH

...FDA approved a 32 mg tablet of Tracleer bosentan to treat pulmonary arterial hypertension in children...
...Johnson & Johnson (NYSE:JNJ) gained Tracleer in its June acquisition of Actelion Ltd. Actelion said Tracleer...
...discovery operations and early stage assets (see BioCentury Extra, Jan. 26 and June 16) . Mary Romeo Tracleer Idorsia...
BioCentury | Jul 27, 2017
Product R&D

Spheres of influence

...pointed to the spheroids’ ability to pick out cytotoxicity of the endothelin receptor antagonists Tracleer bosentan...
...prolonged expression of BSEPs is a potential advantage of the system. Johnson & Johnson obtained Tracleer...
BioCentury | Jul 19, 2017
Company News

China adds drugs to reimbursement list

...drug Zytiga abiraterone and multiple myeloma therapy Velcade bortezomib, but withdrew Remicade infliximab and Tracleer bosentan...
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...bosentan for congestive heart failure (CHF). Roche had discontinued a Phase III trial of bosentan...
...known Orphan indication, pulmonary arterial hypertension (PAH), in parallel with heart failure. FDA approved Tracleer bosentan...
...tied to Tracleer. Despite trials in numerous other indications, the biotech never succeeded in expanding Tracleer’s...
Items per page:
1 - 10 of 493